Feb 4 (Reuters)- Kyorin Pharmaceutical Co., Ltd. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Dec 31, 2025 Dec 31, 2024 Mar 31, 2026 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 92.46 89.29 127.00 (+3.6 pct) (+2.3 pct) (-2.4 pct) Operating 4.61 3.12 6.10 (+47.9 pct) (-35.1 pct) (-51.5 pct) Recurring 5.10 3.75 6.30 (+35.8 pct) (-30.4 pct) (-52.3 pct) Net 4.12 2.44 4.80 (+68.9 pct) (-41.2 pct) (-47.2 pct) EPS 71.71 yen 42.46 yen 83.55 yen Ann Div 57.00 yen 57.00 yen -Q2 div 20.00 yen 20.00 yen -Q4 div 37.00 yen 37.00 yen NOTE - Kyorin Pharmaceutical Co., Ltd.. To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4569.T
TABLE-Kyorin Pharmaceutical - 9-MTH group results
Earlier from Kyorin Pharmaceutical Co.,ltd
- KYORIN Pharmaceutical: Strong nine-month results, but full-year outlook projects lower sales and profits
- KYORIN Pharmaceutical: Net sales rose 6.5% YoY, but operating profit fell on higher R&D; guidance unchanged
- Kyorin Pharmaceutical Co Ltd - Kyorin And Hinge Bio Enter Into A Collaboration And License Agreement Of Hb2198 In Japan For Sle And Other Diseases
- KYORIN Pharmaceutical: Strong Q1 profit growth, but full-year outlook projects lower sales and earnings